川崎病（KD）是儿童期常见的血管炎性疾病，通常会影响5岁以下的儿童。病

Kawasaki disease (KD) is a common childhood vasculitic disease that usually affects children under 5 years of age. <br><br>Pathogen infection is a potential cause of susceptible children [9]. <br><br>It is believed by Marrani et al. that patients with KD have a strong innate immune response, which causes inflammatory damage to systemic blood vessels [10]. But unlike most infectious diseases, there are significant differences between races, indicating that inheritance has a certain pathogenic mechanism in the disease [11]. <br><br>It has been identified by Onouchi through genome-wide association and genome-wide linkage studies that several susceptibility genes (such as ITPKC, CASP3, CD40 and ORAI) and chromosomal regions are related to KD [12]. <br><br>Genetic testing can facilitate the early diagnosis and treatment of KD, and reduce improper treatment of patients with other diagnoses [13]. Coronary artery involvement is the most important complication of Kawasaki disease, which may lead to severe coronary artery stenosis, leading to ischemic heart disease [14]. <br>For KD, the clinical treatment of gamma globulin combined with aspirin is the main treatment [15]. The use of intravenous immunoglobulin (IVIG) and aspirin greatly reduces the incidence of coronary artery disease in sick children [16]. Aspirin is a non-steroidal anti-inflammatory drug that has antipyretic and analgesic effects, and can also inhibit The inflammatory response mediated by prostaglandin inhibits vasculitis, and also has the effect of platelet aggregation, which has a certain control effect on coronary artery damage. In addition, aspirin can also regulate the hypothalamic body temperature regulation center, effectively control the patient's body temperature, and has high safety for patients with Kawasaki disease [17]. The combined application of immunoglobulin and aspirin can play a synergistic effect in alleviating symptoms and improving patients' inflammatory response. However, there is no unified standard for the dose and period of administration of immunoglobulin. Dietz et al. [18] advocated immunoglobulin The applied dose of protein is high dose, in order to quickly control the condition and relieve symptoms. Dionne et al. believe that [19] high-dose intravenous immunoglobulin (2 g/kg, single application) and conventional dose (1g/kg) intravenous immunoglobulin can not only exert a more advantageous clinical therapeutic effect, but also be safe ,effective. At the same time, it also has a very beneficial preventive effect on coronary artery disease, which can reduce its incidence to less than 5% [20].<br>The mechanism of vascular injury in patients with Kawasaki disease is believed to be related to the activation of the mononuclear/macrophage system in the body, which releases a large number of inflammatory mediators and inflammatory factors, causing vascular endothelial damage [21]. Studies have shown [22] TNF-a can stimulate T cells to produce various inflammatory factors and aggravate the inflammatory response. It plays an important role in the body's inflammatory response and immune regulation. CRP can be significantly increased in the early stage of inflammatory reaction. IL-6 is a pro-inflammatory factor, which can stimulate the proliferation and differentiation of T cells and B cells, increase the release of inflammatory factors and aggravate the inflammatory response. This study also confirmed that the levels of the above-mentioned inflammatory factors in the serum of patients with Kawasaki disease were significantly increased before treatment, suggesting that the body has a state of high inflammation. Therefore, for the treatment of Kawasaki disease, reducing the level of inflammatory factors and protecting the function of vascular endothelium is also the key. <br>Although the role of corticosteroids is still controversial [23], more literature supports that glucocorticoids may be beneficial in the treatment of this disease [24]. Gamez et al. believe that the first-line treatment of the disease includes intravenous immunoglobulin and corticosteroids, and that low-dose, short-term hormone therapy has lower side effects and is more acceptable [25]. Studies by Miyata and others have also confirmed that the side effects of low-dose prednisone acetate are relatively small [26]. <br>Our research confirms that: on the basis of oral aspirin treatment, high-dose gamma globulin single-dose pulse therapy combined with low-dose prednisone acetate treatment, patients with TNF-a, CRP, IL-6 and other inflammatory factors lower levels than conventional gamma globulin Protein therapy decreased more significantly (p

Kawasaki disease (KD) is a common vasculitis disease in childhood and usually affects children under 5 years of age.<br><br>Pathogen infection is a potential trigger for susceptible children.<br><br>It is believed by Marrani and others that patients with KD have a strong congenital immune response, which causes inflammatory damage to systemic blood vessels. However, unlike most infectious diseases, there are significant differences in race, indicating that genetics has certain pathogenic mechanisms in the disease.<br><br>It has identified several susceptible genes (e.g. ITPKC, CASP3, CD40 and ORAI) and chromosome regions associated with KD through genome-wide association and genome-wide interlocking studies.<br><br>Genetic testing can make early diagnosis and treatment of KD easier and reduce inappropriate treatment in patients with other diagnoses. Coronary artery injury is the most important complication of Kawasaki disease, which can lead to severe coronary artery stenosis and ischemic heart disease.<br>For KD, clinically, the treatment plan of propylene globulin combined with aspirin is mainly. The use of intravenous immunoglobulin (IVIG) and aspirin greatly reduced the occurrence of coronary artery lesions in sick children, aspirin is a nonsteroidal anti-inflammatory drug, with anti-heat, pain relief effect, but also can inhibit the inflammatory reaction mediated by prostatin, inhibit angiotisitis response, but also has the role of plate plate aggregation, coronary damage has a certain control effect. In addition, aspirin is also able to regulate the hypothyclin thermothermia center, effectively control the body temperature of patients, for patients with Kawasaki disease has a high safety. The combined application of immunoglobulin and aspirin can play a synergy in alleviating symptoms and improving the inflammatory response of patients, but there is currently no uniform standard for the dose and dosage cycle of immunoglobulin, Dietz and others advocate that the dose of immunoglobulin is high dose, with a view to quickly controlling the disease and alleviating symptoms. Dionne and other studies have concluded that high-dose immunoglobulin intravenous injection (2 g / kg, single application) and conventional dose (1g/kg) immunoglobulin intravenous injection can not only play a more advantageous clinical therapeutic effect, but also safe and effective. At the same time, coronary artery lesions also have a very beneficial preventive effect, can reduce its occurrence rate to less than 5%.<br>The mechanism of vascular damage in patients with Kawasaki disease is thought to be related to the activation of monocyte/macrophage systems in the body, thereby releasing a large number of inflammatory media and inflammatory factors, causing endodertic damage to blood vessels. The research shows that TNF-a can stimulate T cells to produce various inflammatory factors and aggravate inflammatory reactions, which play an important role in the body's inflammatory response and immunomodulation. CRP can be significantly increased in the early stages of inflammatory reactions. IL-6 is an inflammatory factor that stimulates the proliferation and differentiation of T- and B-cells, increases the release of inflammatory factors and aggravates inflammatory reactions. This study also confirmed that the above-mentioned inflammatory factor levels increased significantly in the pre-treatment serum of patients with Kawasaki disease, suggesting the presence of a high inflammatory response state in the body. Therefore, for the treatment of Kawasaki disease, reducing the level of inflammatory factors and protecting the endothor function of blood vessels is also the key.<br>Although the role of corticosteroids is still controversial, more literature supports the possible benefits of glucoticoids in the treatment of the disease. Gamez and others believe that the first-line treatment for the disease includes intravenous use of immunoglobulin and corticosteroids, and that low-dose, short-course hormone therapy has lower side effects and is more likely to be accepted. Studies such as Miyata have also confirmed that small doses of pernisone acetate have relatively small side effects.<br>Our study confirmed that, on the basis of oral aspirin therapy, high-dose propylene globulin single-dose impact therapy combined with small-dose percetic acid pernicone therapy, patients with TNF-a, CRP, IL-6 and other inflammatory factors decreased the level of more significantly than conventional propylene globulin therapy (p).

Kawasaki disease (KD) is a common vasculitis disease in childhood, which usually affects children under 5 years old.<br>Pathogen infection is a potential inducement for susceptible children [9].<br>Marrani and others believe that patients with KD have a strong innate immune response, which causes systemic vascular inflammatory damage [10]. But different from most infectious diseases, there are significant differences in race, indicating that there is a certain pathogenic mechanism of heredity in this disease [11].<br>Onouchi has identified several susceptible genes (such as itpkc, CASP3, CD40 and Orai) and chromosomal regions associated with KD [12].<br>Genetic testing can make early diagnosis and treatment of KD easier, and reduce the improper treatment of patients with other diagnosis [13]. Coronary artery involvement is the most important complication of Kawasaki disease, which may lead to severe coronary artery stenosis and lead to ischemic heart disease [14].<br>For KD, gamma globulin combined with aspirin is the main treatment in clinic [15]. The use of intravenous immunoglobulin (IVIG) and aspirin greatly reduced the incidence of coronary artery disease in children [16]. Aspirin is a non steroidal anti-inflammatory drug, which has antipyretic and analgesic effects. At the same time, it can also inhibit the inflammatory response mediated by prostaglandin and inhibit the vascular inflammatory response. At the same time, it also has the effect of platelet aggregation, and has the effect of coronary artery injury It has a certain control effect. In addition, aspirin can regulate the hypothalamic thermoregulation center, effectively control the body temperature of patients, and has high safety for patients with Kawasaki disease [17]. The combination of immunoglobulin and aspirin can play a synergistic role in relieving symptoms and improving inflammatory reaction of patients. However, there is no unified standard for the dosage and administration cycle of immunoglobulin. Dietz et al. [18] advocated that the application dose of immunoglobulin should be high-dose, so as to quickly control the disease and relieve symptoms. Dionne et al. [19] intravenous injection of high-dose immunoglobulin (2 g / kg, single application) and conventional dose (1 g / kg) intravenous injection of immunoglobulin can not only play a more advantageous clinical therapeutic effect, but also be safe and effective. At the same time, it also has a very beneficial preventive effect on coronary artery disease, which can reduce its incidence to less than 5% [20].<br>The mechanism of vascular injury in patients with Kawasaki disease is believed to be related to the activation of monocyte / macrophage system in vivo, which releases a large number of inflammatory mediators and inflammatory factors, causing vascular endothelial damage [21]. Studies have shown that [22] TNF-a can stimulate T cells to produce various inflammatory factors and aggravate the inflammatory response, which plays an important role in inflammatory response and immune regulation. CRP increased significantly in the early stage of inflammatory reaction. IL-6 is a proinflammatory factor, which can stimulate the proliferation and differentiation of T cells and B cells, increase the release of inflammatory factors and aggravate the inflammatory reaction. This study also confirmed that the serum levels of above-mentioned inflammatory factors in patients with Kawasaki disease were significantly increased before treatment, suggesting the existence of a high level of inflammatory response. Therefore, for the treatment of Kawasaki disease, reducing the level of inflammatory factors and protecting vascular endothelial function is also the key.<br>Although the role of corticosteroids is still controversial [23], more literature supports that glucocorticoids may have certain benefits in the treatment of the disease [24]. Gamez et al. Considered that the first-line treatment of the disease included intravenous immunoglobulin and corticosteroids, and believed that the side effects of low-dose and short-term hormone treatment were lower, and were more easily accepted [25]. Miyata and other studies also confirmed that the side effects of small dose prednisone acetate were relatively small [26].<br>Our study confirmed that: on the basis of oral aspirin treatment, high-dose gamma globulin single dose pulse therapy combined with low-dose prednisone acetate treatment, patients with TNF-a, CRP, IL-6 and other inflammatory factors decreased more significantly than conventional gamma globulin therapy (P<br>